Company news
BioRestorative Therapies, Inc. news in 2024
BioRestorative Therapies, Inc.'s news releases, calls and decks from 2024, newest first.
BioRestorative Therapies Announces Notice of Allowance of Key New Patent Protecting ThermoStem® Metabolic Disease Program
December 4, 2024
BioRestorative Ends Q3 In ‘Strong’ Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial
November 20, 2024
BioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data
November 12, 2024
BioRestorative Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update
November 11, 2024
BioRestorative Therapies to Present New Clinical Data at the ORS PSRS 7th International Spine Research Symposium
November 5, 2024
BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health
November 4, 2024
BioRestorative Therapies Receives Patent Allowance for ThermoStem® Metabolic Disease Program
October 30, 2024
BioRestorative Therapies’ IFATS 2024 Presentation to Feature ThermoStem® Platform’s Potential to Deliver a Superior Efficacy and Tolerability Profile Over GLP-1 Drugs
September 18, 2024
BioRestorative Therapies Reports Second Quarter 2024 Financial Results and Provides Business Update
August 12, 2024
BioRestorative Therapies to Report Second Quarter 2024 Financial Results and Host Conference Call on August 13, 2024
August 5, 2024
BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program
June 26, 2024
BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results
June 16, 2024
BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice
May 23, 2024
BioRestorative Therapies (NASDAQ: BRTX) Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics Market
May 14, 2024
BioRestorative Therapies Provides First Quarter 2024 Business Update
May 13, 2024
BioRestorative Therapies Enhances Preclinical Metabolic Program with a Novel Exosome-Based Biologic Targeting Obesity
May 7, 2024
BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
April 29, 2024
BioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics Technology
April 29, 2024
BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment
April 15, 2024
BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease
April 7, 2024
BioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued Warrants
April 2, 2024
BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K
March 31, 2024
BioRestorative Therapies Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $8.1 Million Gross Proceeds Priced At-the-Market
February 5, 2024
BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease
February 4, 2024
Calls in 2024
Decks in 2024
- ORS PSRS 7th International Spine Research Symposium 2024
Conference · 19 slides · Nov 13, 2024
- Investor Presentation (April 2024)
Investor deck · 30 slides · April 2024
- Investor Presentation (March 2024)
Investor deck · 30 slides · Mar 12, 2024
- Investor Presentation (January 2024)
Investor deck · 24 slides · January 2024